[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"moxibustion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:moxibustion":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100638172","moxibustion-for-nocturia-100638172",false,"NCT07598227","Moxibustion for Nocturia","Evaluation of the Efficacy and Safety of Acupoint Moxibustion for Nocturia: A Pilot Study","Inclusion Criteria:\n\n* Patients aged 40 years or older.\n* Experiencing two or more nocturia episodes per night.\n\nExclusion Criteria\n\n* Active urinary tract infection (UTI).\n* Poorly controlled diabetes mellitus (defined as HbA1c \\> 6.5%).\n* Presence of a neurogenic bladder caused by conditions such as multiple sclerosis, Parkinson's disease, stroke, spinal cord injury, or nerve damage resulting from major pelvic surgery.\n* Severe congestive heart failure (New York Heart Association \\[NYHA\\] functional class \\> II).\n* Use of other Traditional Chinese Medicine (TCM) therapies for nocturia symptoms within the past month (30 days).\n* Pregnant women.",true,"ALL","40 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Nocturia, the interruption of sleep due to nighttime voiding, severely compromises quality of life, emotional health, and overall well-being when occurring twice or more per night. Given that some patients experience inadequate responses to conventional Western therapies or harbor concerns about the long-term side effects of pharmaceuticals, many are turning to Traditional Chinese Medicine (TCM) for alternative solutions. This study utilized a randomized clinical trial design to investigate the efficacy and safety of acupoint moxibustion for nocturia.",[27,28,29,30],"Nocturia","Acupoint","Moxibustion","Traditional Chinese Medicine","RECRUITING","2026-05-17",{"date":34,"type":35},"2026-05-20","ACTUAL",{"date":37,"type":35},"2025-01-01",{"date":39,"type":21},"2026-12-31",{"name":41,"class":42},"Buddhist Tzu Chi General Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100531339","moxibustion-for-the-prevention-of-hemorrhagic-cystitis-after-allo-hsct-100531339","NCT06198517","Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT","Clinical Study of Moxibustion for the Prevention of Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. Patients are fully aware of the study, participate voluntarily and sign the informed consent form (ICF);\n2. Age: 14-60 years;\n3. Patients with pernicious blood diseases undergoing allo-HSCT using the MAC protocol or patients with severe aplastic anemia (Severe aplastic anemia; severeaplasticanimin, SAA) undergoing allo-HSCT;\n\nExclusion Criteria:\n\n1. refuse to participate in this clinical study;\n2. The corresponding skin at the moxibustion site is broken or sensitive;\n3. allo-HSCT pretreated with the RIC program;","14 Years","60 Years",{"count":54,"type":21},266,[24],"This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The control group was treated conventionally, and the experimental group increased moxibustion of Zhongji, Guanyuan and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation. Urine routine tests were performed at the time of admission, +1d, and +14d, and urine BK virus, JC virus, and adenovirus were tested at four time points, namely, +1d, +14 days, onset of hematuria symptoms, and remission of HC, respectively; routine urine tests were performed once every 7 days for all patients within 100days. For patients with Hemorrhagic cystitis (HC), daily severity grading, pain scoring, cystitis symptom scoring, use of antispasmodic and analgesic medications, and major TCM evidence were recorded with the aim of evaluating the efficacy of moxibustion in the prevention of HC in this patient population.",[29,58,59,60],"Hematopoietic Stem Cell Transplantation","Hemorrhagic Cystitis","Prevention","2026-03-09",{"date":63,"type":35},"2026-03-12",{"date":65,"type":35},"2024-03-21",{"date":67,"type":21},"2026-09-30",{"name":69,"class":42},"Yi Zhang",4,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":43},"100534626","moxibustion-in-the-treatment-of-hemorrhagic-cystitis-after-allo-hsct-100534626","NCT06241274","Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT","Clinical Study of Moxibustion in the Treatment of Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. patients were fully aware of the study, participated voluntarily, and signed the informed consent form;\n2. Age: 18-55 years old;\n3. patients with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation;\n\nExclusion Criteria:\n\n1. refusal to participate in this clinical study;\n2. broken or sensitized skin corresponding to the moxibustion site;\n3. allogeneic hematopoietic stem cell transplantationpatients pretreated with the Reduced-intensity conditioning.","18 Years","55 Years",{"count":81,"type":21},60,[24],"This study was a prospective, multicenter, single-arm clinical study planned to enroll 60 patients who developed hemorrhagic cystitis after sexually allogeneic hematopoietic stem cell transplantation Patients with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation were given symptomatic supportive treatment combined with moxibustion covering Shenque, Zhongguo, Guanyuan, and Qihai for 30 minutes every day for 14 days and urine routine was collected every day for 14 days to assess the severity of hemorrhagic cystitis and pain scores to evaluate the effectiveness of moxibustion in treating hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.",[29,58,59,85],"Treatment","2024-07-23",{"date":88,"type":35},"2024-07-24",{"date":90,"type":21},"2024-08-15",{"date":92,"type":21},"2025-12-31",{"name":94,"class":42},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"]